Get the Stockscreener App
238.97
1.35%
-3.26
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $238.97, with a volume of 2.52M.
It is down -1.35% in the last 24 hours and up +4.70% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$242.23
Open:
$241.54
24h Volume:
2.52M
Relative Volume:
2.23
Market Cap:
$33.61B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
23.04
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+3.88%
1M Performance:
+4.70%
6M Performance:
+6.34%
1Y Performance:
-11.49%
1-Day Range:
$237.87
$242.57
1-Week Range:
$230.08
$242.63
52-Week Range:
$180.26
$277.67
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
238.97 | 33.61B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
426.70 | 150.74B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
191.75 | 52.23B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.18 | 31.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.96 | 31.55B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-19-26 | Initiated | Rothschild & Co Redburn | Neutral |
| Jul-16-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-13-26 | Downgrade | Citigroup | Buy → Neutral |
| Jun-17-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Mizuho Adjusts Price Target on ResMed to $240 From $235 - www.marketscreener.com
EBITDA of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Q4 2026 Earnings Call Transcript - Benzinga
Is ResMed Facing Fresh Questions Before Results (ASX:RMD)? - Kalkine Media
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com South Africa
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com Nigeria
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Form 4 ResMed Inc For: 8 October By Investing.com - Investing.com Nigeria
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed (NYSE:RMD) Stock: Insider Michael Farrell Sells 4,991 Shares - MarketBeat
ResMed chairman & CEO Michael Farrell sells $1.1m in shares - Investing.com
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
What Is Shaping Breville, Treasury Wine and ResMed? - Kalkine Media
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Michael Farrell proposes selling 4,991 ResMed (NYSE: RMD) shares through Fidelity. - Stock Titan
ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals - ChartMill
ResMed plans USD 1.5 billion share repurchase and RBC raises target for ResMed stock - ad-hoc-news.de
Resmed (ASX:RMD) Shares Slide Over the Year Even as Record Q4 Revenue and a Higher Dividend Close Fiscal 2026 - Kalkine
ResMed stock pre-market at EUR 199.20: plus 0.48 percent - ad-hoc-news.de
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
ResMed Inc Reports CDI and Common Stock Movements for September 2026 - Kalkine
RSMDF | RESMED INC ORD Insider Trading - Quiver Quantitative
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Stifel reiterates Hold on ResMed stock amid market share concerns - Investing.com
ResMed Inc. $RMD Shares Sold by Envestnet Asset Management Inc. - MarketBeat
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
RESMED INC ($RMD) CEO 2026 Pay Revealed - Quiver Quantitative
RESMED INC ($RMD) CEO 2026 Pay Revealed - Quiver Quantitative
RESMED INC SEC Filing (Oct 1, 2026) - Stock Titan
Form 4 ResMed Inc For: 1 October By Investing.com - Investing.com Nigeria
A 10% dividend increase is part of ResMed (RMD)'s FY2027 stockholder return plan. - Stock Titan
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 - Moomoo
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
Form ARS RESMED INC For: Jun 30 - StreetInsider
Will ResMed (ASX:RMD) stay a fund manager favourite? - Kalkine Media
Price to cash flow ratio of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed stock trades at EUR 195.18 after RBC raises target - AD HOC NEWS
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator? - Kalkine Media
Net debt of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
ResMed stock trades at USD 221.89 after RBC target hike - AD HOC NEWS
ResMed stock heads into the open after September 24 data - AD HOC NEWS
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed stock reports 10 percent fiscal revenue growth - AD HOC NEWS
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Oct 07 '26 |
Sale |
226.33 |
4,991 |
1,129,637 |
479,803 |
| Farrell Michael J. | Officer |
Oct 07 '26 |
Proposed Sale |
226.33 |
4,991 |
1,129,638 |
0 |
| Farrell Michael J. | Officer |
Sep 08 '26 |
Proposed Sale |
226.22 |
4,991 |
1,129,064 |
0 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Sale |
222.44 |
4,991 |
1,110,191 |
466,256 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| FARRELL PETER C | Director |
Sep 02 '26 |
Sale |
234.73 |
970 |
227,688 |
51,803 |
| Peter C Farrell | Director |
Sep 02 '26 |
Proposed Sale |
234.65 |
970 |
227,608 |
0 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Sale |
205.69 |
4,991 |
1,026,596 |
466,256 |
| Farrell Michael J. | Officer |
Aug 07 '26 |
Proposed Sale |
205.69 |
4,991 |
1,026,596 |
0 |
0.60%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):